PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
pavmed的股票在公司宣布与Lucid Diagnostics提交其Esoguard食道DNA测试的完整临床证据后上涨。
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
PavMed宣布和Lucid Diagnostics为其Esoguard食道DNA测试提交了完整的临床证据，此后，该公司股价走高。
资讯热榜
更新时间